Rem2 GTPase maintains survival of human embryonic stem cells as well as enhancing reprogramming by regulating p53 and cyclin D1

dc.contributor.authorEdel, Michael John
dc.contributor.authorMenchón Najas, Cristina
dc.contributor.authorMenendez, Sergio
dc.contributor.authorConsiglio, Antonella
dc.contributor.authorRaya Chamorro, Ángel
dc.contributor.authorIzpisúa Belmonte, Juan Carlos
dc.date.accessioned2015-11-12T08:51:45Z
dc.date.available2015-11-12T08:51:45Z
dc.date.issued2010-03-15
dc.date.updated2015-11-12T08:51:46Z
dc.description.abstractHuman pluripotent stem cells, such as embryonic stem cells (hESCs) and induced pluripotent stem cells (iPSCs), have the unique abilities of differentiation into any cell type of the organism (pluripotency) and indefinite self-renewal. Here, we show that the Rem2 GTPase, a suppressor of the p53 pathway, is up-regulated in hESCs and, by loss- and gain-of-function studies, that it is a major player in the maintenance of hESC self-renewal and pluripotency. We show that Rem2 mediates the fibroblastic growth factor 2 (FGF2) signaling pathway to maintain proliferation of hESCs. We demonstrate that Rem2 effects are mediated by suppressing the transcriptional activity of p53 and cyclin D(1) to maintain survival of hESCs. Importantly, Rem2 does this by preventing protein degradation during DNA damage. Given that Rem2 maintains hESCs, we also show that it is as efficient as c-Myc by enhancing reprogramming of human somatic cells into iPSCs eightfold. Rem2 does this by accelerating the cell cycle and protecting from apoptosis via its effects on cyclin D(1) expression/localization and suppression of p53 transcription. We show that the effects of Rem2 on cyclin D(1) are independent of p53 function. These results define the cell cycle and apoptosis as a rate-limiting step during the reprogramming phenomena. Our studies highlight the possibility of reprogramming somatic cells by imposing hESC-specific cell cycle features for making safer iPSCs for cell therapy use.
dc.format.extent13 p.
dc.format.mimetypeapplication/pdf
dc.identifier.idgrec650723
dc.identifier.issn1549-5477
dc.identifier.pmid20231315
dc.identifier.urihttps://hdl.handle.net/2445/67751
dc.language.isoeng
dc.relation.isformatofReproducció del document publicat a: http://dx.doi.org/10.1101/gad.1876710
dc.relation.ispartofGenes and Development, 2010, vol. 24, num. 6, p. 561-573
dc.relation.urihttp://dx.doi.org/10.1101/gad.1876710
dc.rightscc-by-nc (c) Edel, Michael John et al., 2010
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttp://creativecommons.org/licenses/by-nc/3.0/es
dc.sourceArticles publicats en revistes (Ciències Fisiològiques)
dc.subject.classificationCèl·lules mare embrionàries
dc.subject.classificationTeràpia genètica
dc.subject.classificationGenètica molecular
dc.subject.classificationCicle cel·lular
dc.subject.otherEmbryonic stem cells
dc.subject.otherGene therapy
dc.subject.otherMolecular genetics
dc.subject.otherCell cycle
dc.titleRem2 GTPase maintains survival of human embryonic stem cells as well as enhancing reprogramming by regulating p53 and cyclin D1
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion

Fitxers

Paquet original

Mostrant 1 - 1 de 1
Carregant...
Miniatura
Nom:
650723.pdf
Mida:
2.05 MB
Format:
Adobe Portable Document Format